UBS O'Connor’s Vaxcyte PCVX Stock Holding History

UBS O'Connor’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$25K	–	535
2024 Q3	$25K	Hold	10,000	–	–	﹤0.01%	440
2024 Q2	$36.5K	Buy	+10,000	New	+$681K	﹤0.01%	462

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS O'Connor's PCVX Position: Q4 2024 in Review

UBS O'Connor sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 5,307 shares — an estimated $606K sold.

UBS O'Connor first reported a position in PCVX in Q1 2023 and held it in 6 quarters. The position peaked at $606K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

UBS O'Connor reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
UBS O'Connor sold 5,307 Vaxcyte shares in Q4 2024, an estimated $606K.
UBS O'Connor first reported a position in Vaxcyte in Q1 2023 and held it in 6 quarters.
UBS O'Connor's Vaxcyte position peaked at $606K in Q3 2024.
323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on UBS O'Connor's 13F filing for Q4 2024, filed 14 Feb 2025.